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A B S T R A C T
Objective: The purpose of the study was to determine the optimal dosing regimen of intravenous
fosfomycin for the treatment of Pseudomonas aeruginosa (PA) based on PK/PD targets.
Method: A total of 120 PA isolates were recovered from various clinical specimens at university hospital
in Thailand. Minimum Inhibitory Concentrations (MICs) of all the isolates were determined by the E-test
method. PK parameters were obtained from a published study. Monte Carlo simulation was performed to
calculate the percentage of target attainment (PTA) and cumulative fraction of response (CFR).
Results: MIC90 of fosfomycin alone, fosfomycin in combination with carbapenem, carbapenems alone
and carbapenems in combination with fosfomycin were >1,024, 1,024, >32 and 32 mg/ml, for multidrug
resistant (MDR)-PA and 512, 128, 8 and 3 mg/ml respectively, for non-MDR PA. Approximately 40% of the
non-MDR PA were carbapenem-resistant strains. For non-MDR PA with CRPA, fosfomycin 16 g
continuous infusion in combination with carbapenems provided %PTA of approximately 80 and %CFR of
> 88. While, %PTA and %CFR > 90 were achieved with fosfomycin 24 g/day prolonged infusion in
combination with carbapenem.
Conclusions: Prolonged infusion of fosfomycin 16 - 24 g combined with extended carbapenem infusion
could be used in non-MDR PA treatment with CRPA.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pseudomonas aeruginosa (PA) is a highly prevalent pathogen of
nosocomial infections worldwide.1,2 Data from developing coun-
tries indicates that P. aeruginosa is the most common cause of
pneumonia in hospital (29%), and is the third most common cause
of Intensive Care Unit (ICU)-acquired infections (17%).2 The
situation in Thailand is similar, with P aeruginosa being the most
common pathogen of Hospital-Acquired Pneumonia (HAP) in that
country.3 More importantly, it is a common multidrug-resistant* Corresponding author. Department of Pharmacy Practice, Faculty of
Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
E-mail address: paveenasonthi@hotmail.com (P. Sonthisombat).
http://dx.doi.org/10.1016/j.ijid.2016.06.017
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(MDR) gram-negative pathogen causing pneumonia in hospital-
ized patients.3
P. aeruginosa infections have a high rate of mortality (ranging
from 10% to 70%) particularly in patients given inappropriate
empirical therapy, immunocompromised patients, ICU patients
and drug-resistant P. aeruginosa infections.4–8 Drug-resistant P.
aeruginosa in critically ill patients poses a treatment challenge,
with the available antibiotics of choice for this pathogen, such as
carbapenems, becoming gradually less effective.8–10
A combination of antimicrobial agents is a good option for
treatment of drug-resistant P. aeruginosa infections in critically ill
patients.11–13 Colistin has already become a standard of treatment
in patients infected with drug-resistant P. aeruginosa.12,13 Howev-
er, nephrotoxicity associated with colistin means this medicine
should be avoided in some renal insufﬁciency and high riskciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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cin and carbapenems appear to be a possible treatment regimen.14
Intravenous (IV) fosfomycin is an old antibiotic agent which exerts
excellent in vitro bactericidal activity against a wide spectrum of
organisms, including P. aeruginosa, especially in resistant
strains.14–18 In in vitro studies, the combination of fosfomycin
with carbapenems has also shown good synergistic effects against
P. aeruginosa isolates.19 Some clinical trials have reported
improvements in the clinical and microbiological outcomes of
fosfomycin in combination with other antibiotics, such as
carbapenems, for treatment of P. aeruginosa.19–24 However, the
reported appropriate dosage regimen of fosfomycin varied
widely.20–24;
Pharmacokinetic/pharmacodynamic (PK/PD) studies, especially
in Monte Carlo simulations, have played roles for selecting
appropriate antibiotic doses with the goal of increasing treatment
efﬁcacy and reducing the risk of selecting multidrug-resistant
pathogens.25–27 Previous studies that considered antibiotic PK/PD
to optimize exposure when treating resistant bacteria included
many antimicrobial agents such as colistin and piperacillin/
tazobactam. These studies resulted in successful outcomes.28–31
However, previous Monte Carlo simulation studies of PK/PD
dosages did not include fosfomycin.
The purpose of this current study was to ﬁnd the optimal dosage
regimen of fosfomycin when used in combination with carbape-
nem for the treatment of non-MDR-PA and MDR-PA based on PK/
PD targets in critically ill patients.
2. Materials and methods
2.1. Microbiology
P. aeruginosa isolates recovered from various clinical specimens
(sputum, urine, skin and soft tissue, blood, pleural ﬂuid) at the
Faculty of Medicine at Siriraj Hospital in Bangkok, Thailand, were
collected between June and September 2011. A total of 120 non-
MDR and MDR isolates were obtained. Minimum inhibitory
concentrations (MICs) of carbapenems (imipenem, meropenem
and doripenem) and fosfomycin by E test were determined for all
isolates. Isolate preparation was performed according to the
Clinical and Laboratory Standards Institute (CLSI 2011) protocol.32
The MDR phenotype was identiﬁed for isolates expressing
resistance to at least three different antibiotic groups: beta-
lactams (penicillin, cephalosporin or carbapenems (except mono-
bactam e.g. aztreonam), aminoglycosides and ﬂuoroquinolones.33
Synergy studies were conducted using an E test of fosfomycin in
combination with carbapenems. E test strips of each drug used in
the combination were applied in cross direction to each other and
the MIC values of each drug were measured after combination.34,35
2.2. Pharmacodynamic Model
Pharmacodynamic exposure was measured by percentage of
time above the MIC (%T > MIC) of each drug.18,36–40 Simulations
were conducted for IV infusions of the various agents and
regimens: fosfomycin 1- 8 g given every 6 - 12 hours, infused
over 30 minutes - 24 hours, meropenem 0.5 – 2.0 g given every 6 -
8 hours, infused over 30 minutes - 3 hours, imipenem 0.5 - 1.0 g
given every 6 - 8 hours, infused over 30 minutes - 3 hours, and
doripenem 0.5-2.0 given every 8 hours, infused over 30 minutes -
4 hours. PK/PD targets were deﬁned as 70% T>MIC for fosfomycin.
This breakpoint (70% T>MIC) applies when effective dosage
regimens for all cell wall-active antimicrobials require serum
drug concentrations exceeding the MIC of the pathogens 18,36–40
and 40% T>MIC for the carbapenems. The value 40% T>MIC isrequired for near-maximal bactericidal effect of the dosing interval
for Pseudomonas aeruginosa.37,39,40
2.3. Pharmacokinetic Model
Pharmacokinetic data were obtained from previously published
studies of critically ill patients.41–44 A set of parameters was
randomly generated according to each mean and standard
deviation of the parameters. Steady-state concentration versus
time was simulated using a one-compartment model for fosfo-
mycin41 and a two-compartment model for carbapenems to
calculate %T>MIC.42–44
2.4. Monte Carlo Simulation
Pharmacodynamic/pharmacokinetic analysis was conducted
via a 10,000-subject Monte Carlo simulation (Crystal Ball
2010 v.2.2; Decisioneering Inc., Denver, CO) for IV dosage regimens
of fosfomycin and carbapenems to calculate %T> MIC based on the
linear pharmacokinetic behavior of each agent. Log-normal
distributions were evaluated for between-patient variability. The
probability of target attainment (PTA) was calculated as the
percentage of all 10,000 estimates that had a probability of
attaining 40% T>MIC for carbarpenems and 70% T>MIC for
fosfomycin, either used alone or in combination. The cumulative
fraction of response (CFR) was calculated as the proportion of %PTA
of each MIC according to the MIC distribution. The PTA and CFR 
90% was considered optimal against a bacterial population,
whereas a CFR between 80% and 90% was associated with
moderate probabilities of success.36,45
3. Results
MDR-PA had MIC90>1,024 mg/ml for fosfomycin monotherapy,
1,024 mg/ml for fosfomycin combined with carbapenems, >32 mg/
ml for carbapenems monotherapy, and 32 mg/ml for carbapenems
combined with fosfomycin (Table 1). While, MIC90 for non-MDR PA
were 512 mg/ml for fosfomycin monotherapy, 128 mg/ml for
fosfomycin combined with carbapenems, >32 mg/ml, 8 mg/ml
and 4 mg/ml for imipenem, meropenem, and doripenem mono-
therapy, respectively. For carbapenem combination, MIC90 were
12 mg/ml for imipenem combined with fosfomycin, 3 mg/ml for
meropenem combined with fosfomycin and 2 mg/ml for doripe-
nem combined with fosfomycin, respectively. The doripenem
combination with fosfomycin had a MICs lower than the other
carbapenems (Figure 1). Approximately 40% of non-MDR-PA was
carbapenem-resistant PA (CRPA).
A combination of fosfomycin and carbapenems decreases the
MIC of CRPA. Doripenem alone has an MIC90 of 6 mg/ml, and
fosfomycin alone has an MIC90 of 1024 mg/ml, whereas the
combination of fosfomycin with doripenem decreases the MIC90 of
doripenem to 2 mg/ml and fosfomycin to 128 mg/ml.(Table 1).
3.1. %PTA of fosfomycin monotherapy
Analyses of various fosfomycin regimens to test %PTA against
MICs of PA for the fosfomycin monotherapy are shown in
Figure 2. All fosfomycin dosage regimens achieved more than
90% PTA at MIC < 3 mg/ml. Prolonged and continuous infusions
have been shown to improve PK/PD exposure compared to dosage
regimens using traditional 30-minute infusions. At the suscepti-
bility breakpoint (MIC < 32 mg/ml) from the European Committee
on Antimicrobial Susceptibility Testing (EUCAST), fosfomycin
4 g every 8 hr or more dose achieved above 90% PTA. For MIC
64 mg/ml, fosfomycin 4 g every 4 hr or more dose or prolonged
infusion achieved above 90% PTA. No fosfomycin monotherapy
Table 1
MICs of non-MDR PA and MDR PA isolates against tested agents, mono drugs and combination drugs.
Antimicrobial agent Antimicrobial mono
and combination drugs
Non-MDR MDR#
MIC range (mg/ml) MIC90 (mg/ml) MIC90 Of CRPA* (mg/ml) MIC range (mg/ml) MIC90 (mg/ml)
Imipenem monodrug 0.75 - >32 >32 >32 1.0->32 >32
IPM + FOF 0.047 - > 32 12 12 0.38-32 32
Meropenem monodrug 0.016 - >32 8 >32 1.0->32 >32
MEM + FOF 0.006 - 32 3 6 0.38-32 32
Doripenem monodrug 0.023 - >32 4 6 0.5->32 >32
DOM + FOF 0.006 - >48 2 2 0.38-32 32
Fosfomycin monodrug 1.5 - >1024 512 >1024 8.0 - >1024 >1024
FOF + IPM 1.0 - 1024 128 192 8.0 - 1024 1024
FOF + MEM 0.75 - 1024 128 192 8.0 - 1024 1024
FOF + DOM 0.064 -1024 128 128 8.0 - 1024 1024
MDR= multidrug resistance, MICs=minimum inhibitory concentrations (mg/ml), PA=P.aeroginosa, CRPA= carbapenem-resistant P.aeroginosa, FOF = fosfomycin,
DOM=doripenem, IPM=imipenem, MEM=meropenem., *= 40% of CRPA in non-MDR isolates, The susceptibility breakpoint MIC for carbapenems is less than 2 ug/ml. #
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>1024 mg/ml for non-MDR-PA and MDR-PA, respectively.
3.2. %PTA of fosfomycin combination with carbapenem
The %PTA in each combination of fosfomycin and carbapenem
which achieved more than 70% T>MIC90 and 40% T>MIC90,
respectively, for non-MDR PA, are summarized in Table 2. For
MDR-PA, all fosfomycin combinations, with carbapenems, could
not achieve the PK/PD targets. For non-MDR PA, fosfomycin 16 g
continuous infusion combined with meropenem 1- 2 g, 3-hour
infusion every 8 hours and doripenem 1 g, 4-hour infusion every
8 hours achieved approximately 80% for MIC90 128 mg/ml of
fosfomycin, 3 mg/ml for meropenem and 2 mg/ml doripenem
(Table 2). The highest dose of fosfomycin, 8 g every 8 hours
infusion over 6 hours in combination with high-dose meropenem
or doripenem prolonged infusion can achieve better than 95% PTA.
Imipenem combined with fosfomycin achieved the PK/PD target at
MIC90 of non-MDR PA of less than 70%.
Considering the CRPA subgroup, fosfomycin 16 g continuous
infusion combined with doripenem 1 g, 4-hour infusion every
8 hours achieved approximately 80% of PTA for MIC90Figure 1. Minimum inhibitory concentrations (MICs) distribution of drugs in combination
IPM=imipenem, MEM=meropenem, doripenem combination with fosfomycin had MICs l
MIC50 was 48 mg/ml.(128 mg/ml of fosfomycin, 2 mg/ml of doripenem) and combined
with meropenem 2 g, 3-hour infusion every 8 hours, or Imipenem
higher dose prolonged infusion, achieved the PK/PD target at MIC90
of CRPA less than 50% PTA. The highest dose of fosfomycin, 8 g every
8 hours infusion over 6 hours in combination with doripenem
prolonged infusion, can achieve better than 95% PTA. High-dose
meropenem prolonged infusion in combination with the highest
dose of fosfomycin, 8 g every 8 hours infusion over 6 hours,
achieved better than 65% PTA at MIC90 of CRPA (192 mg/ml of
fosfomycin, 6 mg/ml of meropenem). For PTA of more than 90% of
meropenem in combination with fosfomycin, the dosage should be
fosfomycin, 8 g every 8 hours infusion over 6 hours in combination
with meropenem 2 g every 8 hr prolonged infusion at MIC90 less
than 128 mg/ml of fosfomycin and less than 6 mg/ml for mer-
openem. All Imipenem regimen combinations with the highest dose
of fosfomycin, 8 g every 8 hours infusion over 6 hours achieved less
than 50% PTA at MIC90 of CRPA combination.
3.3. %CFR of fosfomycin combination with carbapenem
For non-MDR PA, fosfomycin 16 g continuous infusion com-
bined with prolonged infusion of meropenem (1-2 g infusion over for carbapenem-resistant P.aeroginosa (CRPA), FOF = fosfomycin, DOM=doripenem,
ower than the other carbapenems. MIC90 of fosfomycin in CRPA was 128 mg/ml and
Figure 2. The probability of target attainment (%PTA) of fosfomycin monotherapy achieve more than 70% time above MIC.
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every 8 hours) achieved CFR of more than 88% (Table 3). The CFR
was more than 90% with fosfomycin 8 g prolonged infusion (at
least 6 hours) every 8 hours combined with high-dose prolonged
infusion of meropenem or doripenem. However, PK/PD targets of
%CFR for MDR-PA strains were not achieved for any fosfomycin-
carbapenem combinations.
For the CRPA subgroup, fosfomycin 16 g continuous infusion
combined with doripenem 1 g, 4-hour infusion every 8 hours or
meropenem 2 g, 3-hour infusion every 8 hours achieved approxi-
mately 80% CFR. The highest dose of fosfomycin, 8 g every 8 hours
infusion over 6 hours in combination with doripenem high dose
prolonged infusion can achieve approximately 90%CFR and with
high-dose meropenem (2 g, 3-hour infusion every 8 hours
prolonged infusion) achieve above 85%CFR. The combination of
fosfomycin with imipenem achieved less than 50% CFR.
4. Discussion
P. aeruginosa infections are likely to affect critically ill patients
who require intensive care and treatment with antimicrobial
agents. ICUs have a high prevalence of P. aeruginosa and theTable 2
The maximum of %PTA for fosfomycin (FOF) achive more than 70% time above MIC90 an
above MIC90 of non MDR-PA
* when combinations.
%PTA of combinations IPM
1 g q 8 h
IPM
1 g in 3 h q 8 h
DOM
1 g q 8 h
DOM
1 g in 4
FOF 4 g q 12 h 0 0 0 0 
FOF 8 g q 12 h 0 0 0 0 
FOF 4 g q 8 h 1 2 2 3 
FOF 4 g q 6 h 11 23 23 24 
FOF 8 g q 8 h 30 30 49 49 
FOF 16 g
continuous infusion
32 33 77 80 
FOF 8 g in 6 h
q 8 h
34 35 93 95 
* fosfomycin combined with carbapenems had MIC90 12 mg/ml for imipenem combine
for doripenem combined with fosfomycin and 128 mg/ml for fosfomycin combined wit
# The PTA  90% was considered optimal against a bacterial population, whereas a PTplacement of several invasive devices introduces multiple
opportunities for failure of infection control, resulting in ICUs
being under considerable pressure to select broad-spectrum
antibiotics.1,11,46 The PK of antimicrobial agents in critically ill
patients varies especially in volume of distribution (Vd) and
clearance (CL), which may affect the drug concentration at the
target sites.47 Thus, our study chose published phamacokinetic
studies of critically ill patients. Knowing the PK/PD properties of
the drugs used for the management of critically ill patients is
essential for selecting the appropriate dosage regimens, which will
ﬁnally optimize patient outcomes.48
Fosfomycin inhibits uridine diphosphate-N-acetylglucosamine
enolpyruvyl transferase, which is a key enzyme in early bacterial cell-
wall synthesis steps.49The MICs of fosfomycin for P. aeruginosa in our
study were within the range of 1.5 - >1024 mg/ml which were higher
than the range indicated in other studies (1-512 mg/ml).38 In our
study, the MIC90 for non-MDR PA (512 mg/ml) and MDR-PA
(>1024 mg/ml) were higher than those in other studies (128 and
512 mg/ml for non-MDR PA and MDR-PA, respectively).14,15,38,49
However, a study in a teaching hospital in Thailand showed similar
results to our study. That study reported MICs in the range
2->1024 mg/ml and MIC90 of > 1024 mg/ml.
50 Therefore, we maked carbapenem (doripenem (DOM), imipenem (IPM), meropenem (MEM)) 40% time
 h q 8 h
MEM
1 g q 8 h
MEM
1 g in 3 h q 8 h
MEM
2 g q 8 h
MEM
2 g in 3 h q 8 h
0 0 0 0
0 0 0 0
3 3 3 3
24 24 24 24
49 49 50 50
80 80 80 80
95 96 96 96
d with fosfomycin, 3 mg/ml for meropenem combined with fosfomycin and 2 mg/ml
h carbapenems
A between 80% and 90% was associated with moderate probabilities of success.
Table 3
%CFR of fosfomycin(FOF) - carbapenems combination regimens ((doripenem (DOM), imipenem (IPM), meropenem (MEM)) of non-MDR PA.
%CFR of combinations IPM
1 g q 8 h
IPM
1 g in 3 h q 8 h
DOM
1 g q 8 h
DOM
1 g in 4 h q 8 h
MEM
1 g q 8 h
MEM
1 g in 3 h q 8 h
MEM
2 g q 8 h
MEM
2 g in 3 h q 8 h
FOF 4 g q 12 h 19 22 22 23 21 21 21 21
FOF 8 g q 12 h 11 13 12 13 12 12 12 12
FOF 4 g q 8 h 49 53 51 51 51 52 52 52
FOF 4 g q 6 h 65 74 69 72 75 75 75 76
FOF 8 g q 8 h 70 72 76 80 82 82 83 83
FOF 16 g continuous infusion 71 72 83 88 88 88 88 88
FOF 8 g in 6 h q 8 h 75 76 87 93 89 92 93 93
#The CFR  90% was considered optimal against a bacterial population, whereas a CFR between 80% and 90% was associated with moderate probabilities of success.
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general hospital, as indicated in that previous study, might be due to
the high antimicrobial consumption rate in the teaching hospital.51
Our study had 40% of CRPA indicating a high prevalence of
carbapenem-non susceptible P. aeruginosa in this teaching hospital.
Therefore, monotherapy of fosfomycin in our study could not achieve
the target indicated above. However, the combination of fosfomycin
and carbapenem in our study showed decreased MICs of PA for both
drugs. In the CRPA subgroup in our study, the combination of
fosfomycin and doripenem decreased the MIC of the doripenem to
2 mg/ml, and the fosfomycin in combination with meropenem
decreased the MIC of meropenem by more than a third (Table 1). This
was similar to an in vitro combination study which found that
fosfomycin combined with carbapems decreased the MIC of both
drugs together in combination.19
PD studies of fosfomycin show a time-dependent killing
effect on Staphylococcus aureus and P. aeroginosa. In contrast, its
effectiveness in killing Escherichia coli or Proteus mirabilis is
concentration- dependent activity.15,18,38 Thus, the most pre-
dictive PK/PD parameter of fosfomycin for P. aeruginosa
eradication is the time that the drug is present in the blood
at or above the minimum inhibitory concentration
(T>MIC).18,37,38 The PK/PD targets in this study were chosen
for their propensity to achieve the greatest %PTA and %CFR of
70% T>MIC for fosfomycin. However, these targets were
determined based on limited information. Basically, effective
dosage regimens for all time-dependent antimicrobials require
serum drug concentrations exceeding the MIC of the causative
pathogen for at least 40 to 70% of the dosing interval in the
immunocompetent host,52–54 although %T>MIC of 70 - 100% is
required in difﬁcult-to-treat infections and/or in cases with
neutropenia.47,52,53 These compounds which have the ability to
inhibit bacterial cell wall synthesis may be shared with
fosfomycin. As well, fosfomycin has a PAE of approximately
0.3-5.5 hours for P. aeruginosa.38 Thus, 70% - 100% of the time
above MIC could be appropriate for fosfomycin in the treatment
of P. aeruginosa in critically ill patients. In addition, there is clear
evidence suggesting that carbapenems require a PK/PD target of
40% T>MIC for the treatment of gram-negative infection in
critically ill patients.37–39 For the combination model in our
study, we calculated two achievable treatment targets for each
patient. First, the 70 - 100% T>MIC of fosfomycin, and second,
the PK/PD target of 40% T>MIC for carbapenems. This approach
taken in our study has been described in published PK/PD
combination model studies.54
In our Monte Carlo simulation, we tested both the maximum
recommended dose of fosfomycin monotherapy, which is 16 g/day,
and also the highest dose of 24 g/day with prolonged or continuous
infusion. These simulations were carried out on both non-MDR PA
and MDR PA samples. We found that for monotherapy of
fosfomycin, neither dosages achieved 80-90% of CFR or PTA in
either non-MDR PA or MDR PA. Likewise, other PK studies offosfomycin in critically ill patients have shown that IV 8 g every
8 hours, with a mean of Cmax 307  101 mg/ml,55 could not achieve
the PK/PD target at MIC90 (> 1024 mg/ml) when applied to all PA
groups in our study. The reason is a higher MIC90 of all PA in our study
as we discussed above.
However, our study of the combination of fosfomycin with
carbapenems in non-MDR PA found that 8 g of fosfomycin given
every 8 hours for prolonged infusion over 6 hours in combination
with carbapenems showed %PTA or %CFR more than 90%.
Fortunately, in CRPA,
the combination of high dose prolonged infusion fosfomycin
and doripenem showed greater than 95% PTA at MIC90 and
approximately 90% CFR. Meropenem in combination with fosfo-
mycin in the CRPA group had 85% CFR but 65% PTA at
MIC90. However, 90% PTA of high dose prolonged infusion
fosfomycin and meropenem can achieve at MIC90 less than
128 mg/ml of fosfomycin and less than 6 mg/ml for meropenem.
Fosfomycin in combination with imipenem achieved %PTA and
%CFR less than 50% at very high MIC90 of imipenem for PA in our
study. Thus, empirical therapy for treating PA with area high MIC
(less than 128 mg/ml) can use high dose prolonged infusion of
fosfomycin and doripenem and a more speciﬁc therapy of high
dose prolonged infusion of either fosfomycin in combination with
doripenem or fosfomycin in combination with meropenem. Our
results are similar to those of other PK studies, which calculated
that the steady state average concentration (Cssave) of fosfomycin
8 g IV every 8 hours (24 g/day) was 184 mg/ml in the abscess
ﬂuid.56 This level was more than the MIC90 (128 mg/ml) in non-
MDR PA and CRPA of fosfomycin combined with carbapenems in
our study.
Although 24 g/day of fosfomycin in combination might be
promising, this high dose may cause adverse side effects. The
reported adverse effects from IV fosfomycin in a clinical trial57
were hypokalemia (26%), followed by pain at the injection site (4%)
and heart failure or hypertension (3%). However, some small
clinical studies of high dose fosfomycin (24 g) did not show those
side effects.58
Alternatively, continuous fosfomycin 16 g infusion combina-
tion with doripenem 1 g with 4- hour infusion every 8 hours had
80%PTA at MIC90 (128 mg/ml) of non-MDR PA or CRPA and CFR was
more than 88% at MIC90 and 80% at MIC90 respectively. Thus, this
regimen might be an option for combination therapy when
empirically or speciﬁcally treating PA with high MIC (less than
128 mg/ml). However, the loading dose of fosfomycin needed in a
continuous infusion regimen will apply. Clinical data suggests that
prolonged infusions of beta-lactams are effective for gram-
negative infections treatment. Meta-analysis studies have found
that prolonged infusions of piperacillin-tazobactam in critically ill
patients were associated with a mortality beneﬁt compared with
intermittent infusions.27–30
Our Monte Carlo simulation for monotherapy of fosfomycin
might be effective regimen guides (ﬁgure 1) when we only know
O. Asuphon et al. / International Journal of Infectious Diseases 50 (2016) 23–2928the MIC of fosfomycin before combinations. A PTA of more than
80 - 90% at MIC less than 32 mg/ml (EUCAST ‘s susceptibility
breakpoint of fosfomycin for P.aeruginosa59) was achieved by
fosfomycin monotherapy of 4 g IV every 8 hours, 8 g IV every
12 hours or higher dose. This is similar to the result from a PK study
which showed fosfomycin 8 g IV every 12 hours could achieve a
MIC less than 32 mg/ml.60
Limitations of this study are as follows. First, we did not
simulate the drug level in renally-impaired patients. These
patients usually have a high level of drug concentration in the
blood which would lower the dosage requirements.27,43 Second,
the isolates of the P. aeruginosa were from MIC distributions at
the University Hospital, Bangkok, which might be different from
those taken from other hospitals or in other countries. These are
factors which may well affect the antimicrobial combination of
the dose based on the CFR results.39 Third, the one compartment
model used to simulate the fosfomycin level in our study is
different from the two compartment model in a recently
published article.61 Nonetheless, for the purpose of calculating
T>MIC, there should not be a great difference between these
two models. Fourth, our simulation was based on plasma
phamacokinetics and not on tissue pharmacokinetics. However,
fosfomycin has good penetration to tissue, almost entirely
unbound to proteins. Several investigations in vivo have
conﬁrmed the achievement of a complete concentration
equilibrium between plasma and in-tissue ﬂuid shortly after
administration. Similarly, PK studies on many tissue levels (skin,
urine, lung) showed little difference in plasma.41,56,62 Therefore,
our results might be applicable to those sites of infection. Fifth,
fosfomycin PK/PD targets were determined based on limited
information but we chose by considering the most important
information about compounds which have the ability to inhibit
bacterial cell wall synthesis.47,52,53 Finally, during the period of
our study we could not ﬁnd a previous population PK study of
fosfomycin, thus, we chose a PK study of fosfomycin in critically
ill patients.
5. Conclusion
The PTA and CFR 80- 90% were considered optimal against a
bacterial population. Any monotherapy or combination of
fosfomycin regimen achieved this target for both of our MDR
groups. fosfomycin in combination with imipenem did not achieve
this target in any of our PA groups. However, The combination of
fosfomycin with doripenem achieved the target especially in CRPA.
Fosfomycin in combination with meropem achieved the target,
shown only by the CFR result. Therefore, it is suggested that 8 g IV
every 8 hours with prolonged infusion of more than 6 hours
combination with doripenem 1 g infused 4 hours every 8 hours can
be used for non-MDR PA with CRPA with empirical therapy.
Optionally, a regimen of continuous fosfomycin 16 g infusion in
combination with doripenem could be used. For speciﬁc treatment,
high dose prolonged infusion of fosfomycin in combination with
high dose prolong infusion of meropenem or doripenem (MIC90 of
combination less than 128 mg/ml for fosfomycin and less than
6 mg/ml for meropenem and less than 2 mg/ml for doripenem) may
be necessary.
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